论文部分内容阅读
目的探讨头孢吡肟治疗社区获得性肺炎的的临床效果及安全性。方法对2007年12月至2009年6月新疆医科大学第五附属医院综合内科收治60例患者采用单盲、随机对照试验研究。将60例随机分为头孢吡肟治疗组(31例)及莫西沙星对照组(29例);所有研究均以7～10d为一个疗程。观察治疗组与对照组的临床疗效、不良反应。结果治疗组和对照组的临床有效率分别为90.3%和58.6%,不良反应发生率头孢吡肟高于莫西沙星(25.8%对24.1%),差异无统计学意义(P>0.05),主要不良反应为消化道症状及头痛。结论头孢吡肟是治疗社区获得性肺炎安全有效的药物。
Objective To investigate the clinical efficacy and safety of cefepime in the treatment of community-acquired pneumonia. Methods From December 2007 to June 2009, 60 patients admitted to General Hospital of the Fifth Affiliated Hospital of Xinjiang Medical University were studied by single-blind randomized controlled trial. Sixty patients were randomly divided into cefepime treatment group (n = 31) and moxifloxacin control group (n = 29). All the studies were treated for 7-10 days. The clinical efficacy and adverse reactions of the treatment group and the control group were observed. Results The clinical effective rates of the treatment group and the control group were 90.3% and 58.6% respectively. The incidence of adverse reactions was higher than that of moxifloxacin (25.8% vs 24.1%), with no significant difference (P> 0.05) Adverse reactions to gastrointestinal symptoms and headache. Conclusion Cefepime is a safe and effective drug for the treatment of community-acquired pneumonia.